| 1 |
34480108 | Impact of genetic variation in CYP2C19, CYP2D6, and CYP3A4 on oxycodone and its metabolites in a large database of clinical urine drug tests. | 2022 Feb |
4 |
| 2 |
35201310 | Risk of Opioid Overdose Associated With Concomitant Use of Oxycodone and Selective Serotonin Reuptake Inhibitors. | 2022 Feb 1 |
1 |
| 3 |
33085221 | Projected Utility of Pharmacogenomic Testing Among Individuals Hospitalized With COVID-19: A Retrospective Multicenter Study in the United States. | 2021 Jan |
1 |
| 4 |
33387367 | Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. | 2021 Oct |
1 |
| 5 |
33799050 | Oxycodone findings and CYP2D6 function in postmortem cases. | 2021 Jul |
2 |
| 6 |
34267337 | Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone). | 2021 Jul 15 |
2 |
| 7 |
34565798 | Correction: Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone). | 2021 Sep 27 |
1 |
| 8 |
34575542 | Contribution of CYP2D6 Functional Activity to Oxycodone Efficacy in Pain Management: Genetic Polymorphisms, Phenoconversion, and Tissue-Selective Metabolism. | 2021 Sep 14 |
5 |
| 9 |
34581987 | Sex and Estrous Cycle Differences in Analgesia and Brain Oxycodone Levels. | 2021 Dec |
4 |
| 10 |
34922356 | Urinary Pharmacokinetics of Immediate and Controlled Release Oxycodone and its Phase I and II Metabolites using LC-MS/MS. | 2021 Dec 18 |
1 |
| 11 |
31925778 | Physiologically based pharmacokinetic modelling of oxycodone drug-drug interactions. | 2020 Feb |
3 |
| 12 |
29714124 | Clinical application of pharmacogenetics in pain management. | 2018 Mar |
1 |
| 13 |
29801577 | Pharmacogenetics in Pain Treatment. | 2018 |
1 |
| 14 |
30425549 | CYP2D6 genotype can help to predict effectiveness and safety during opioid treatment for chronic low back pain: results from a retrospective study in an Italian cohort. | 2018 |
2 |
| 15 |
27692933 | Characterization of oxycodone in vitro metabolism by human cytochromes P450 and UDP-glucuronosyltransferases. | 2017 Sep 10 |
1 |
| 16 |
28244808 | CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients. | 2017 Mar |
4 |
| 17 |
28340451 | The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide. | 2017 Apr |
1 |
| 18 |
28769582 | CYP2D6 phenotypes are associated with adverse outcomes related to opioid medications. | 2017 |
1 |
| 19 |
27388970 | The role of cytochrome P450 pharmacogenomics in chronic non-cancer pain patients. | 2016 Nov |
1 |
| 20 |
27702939 | Degradation of Opioids and Opiates During Acid Hydrolysis Leads to Reduced Recovery Compared to Enzymatic Hydrolysis. | 2016 Oct |
1 |
| 21 |
24975450 | CYP2D6-inhibiting drugs and the increased risk of fall-related injuries due to newly initiated opioid treatment--a Swedish, register-based case-crossover study. | 2015 Feb |
2 |
| 22 |
25948306 | [Interindividual variation of pharmacokinetic disposition of and clinical responses to opioid analgesics in cancer pain patients]. | 2015 |
1 |
| 23 |
26447442 | Pharmacogenetics: Using Genetic Information to Guide Drug Therapy. | 2015 Oct 1 |
1 |
| 24 |
24495562 | The CYP2D6 gene determines oxycodone's phenotype-specific addictive potential: implications for addiction prevention and treatment. | 2014 Mar |
5 |
| 25 |
24517173 | Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness. | 2014 May |
4 |
| 26 |
24523296 | Observations of urinary oxycodone and metabolite distributions in pain patients. | 2014 Apr |
1 |
| 27 |
25121773 | Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients. | 2014 |
1 |
| 28 |
25518025 | Prediction of Metabolic Interactions With Oxycodone via CYP2D6 and CYP3A Inhibition Using a Physiologically Based Pharmacokinetic Model. | 2014 Dec 17 |
1 |
| 29 |
23555934 | CYP2D6 genotype dependent oxycodone metabolism in postoperative patients. | 2013 |
4 |
| 30 |
23588782 | Applications of CYP450 testing in the clinical setting. | 2013 Jun |
1 |
| 31 |
23605691 | Cytochrome P450-mediated changes in oxycodone pharmacokinetics/pharmacodynamics and their clinical implications. | 2013 May |
2 |
| 32 |
23783165 | Putative association of ABCB1 2677G>T/A with oxycodone-induced central nervous system depression in breastfeeding mothers. | 2013 Aug |
1 |
| 33 |
21735164 | Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study. | 2012 Jan |
2 |
| 34 |
22148986 | Is maternal opioid use hazardous to breast-fed infants? | 2012 Jan |
1 |
| 35 |
22452458 | Pharmacogenetics of opioids for the treatment of acute maternal pain during pregnancy and lactation. | 2012 Jul |
2 |
| 36 |
22694279 | Preventing opioid-related deaths in children undergoing surgery. | 2012 Jul |
1 |
| 37 |
22747548 | Non-analgesic effects of opioids: interactions between opioids and other drugs. | 2012 |
1 |
| 38 |
23226064 | Pharmacogenomic considerations in opioid analgesia. | 2012 |
4 |
| 39 |
20857093 | Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. | 2011 Jan |
2 |
| 40 |
21173180 | Miconazole oral gel increases exposure to oral oxycodone by inhibition of CYP2D6 and CYP3A4. | 2011 Mar |
1 |
| 41 |
21174486 | Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groups. | 2011 Jan 1 |
1 |
| 42 |
21209234 | CYP3A5*3 affects plasma disposition of noroxycodone and dose escalation in cancer patients receiving oxycodone. | 2011 Nov |
2 |
| 43 |
19719813 | Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia. | 2010 Feb |
3 |
| 44 |
19755414 | Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone. | 2010 Jan |
1 |
| 45 |
20504256 | Personalized therapy in pain management: where do we stand? | 2010 Jun |
1 |
| 46 |
20590587 | The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. | 2010 Jun |
4 |
| 47 |
20590588 | Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. | 2010 Jun |
6 |
| 48 |
20642550 | Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. | 2010 Jul |
12 |
| 49 |
29913934 | Does co-administration of paroxetine change oxycodone analgesia: An interaction study in chronic pain patients. | 2010 Jan 1 |
3 |
| 50 |
19281600 | The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism. | 2009 Apr |
2 |